Nutrition for Asthmatics with Obesity

February 3, 2025 updated by: Jacob T. Mey, PhD RD, Pennington Biomedical Research Center

Nutritional Strategies to Enhance Lung Function in Asthmatics with Obesity

This study will test the effect of diet on asthma in individuals with obesity.

Study Overview

Status

Completed

Conditions

Detailed Description

This is a crossover design pilot trial that will recruit 12 adults with obesity and asthma. Participants will undergo screening and a lead-in period before being randomized to a series of three, 7-day diets with a 7+ day washout period between each diet. Asthma control and lung function will be assessed at the completion of each diet.

The goal of this pilot trial is to understand the effect of diet on asthma and conduct an exploratory analysis on factors that may predict the response to diet.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Louisiana
      • Baton Rouge, Louisiana, United States, 70808
        • Pennington Biomedical Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age: 18-65 years
  • BMI: 30-45 kg/m2
  • asthma diagnosed by medical specialist (confirmed in medical history)
  • partly controlled or uncontrolled asthma by Asthma Control Test score ≤22
  • owns a device compatible with ZEPHYRx platform
  • stable asthma medication use (no change in the past 2 months).

Exclusion Criteria:

  • Diabetes or using diabetes medications that may lower blood glucose levels
  • point of care fasting blood glucose ≥126 mg/dl or triglycerides ≥400 mg/dl
  • current smoking or smoking history of greater than 10 pack-years
  • other significant respiratory or cardiac disease or the presence of clinically important comorbidities, e.g., COPD, renal failure, liver disease; uncontrolled hypertension defined as systolic blood pressure ≥160 mm/Hg, or diastolic blood pressure ≥100 mm/Hg
  • pregnant or nursing women
  • food preferences or allergies inconsistent with study diet capabilities
  • noncompliance with lead-in period requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dietary Guidelines for Americans
7 days of a diet consistent with the Dietary Guidelines for Americans (DGA).

A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)

Including:

  • A variety of vegetables and fruits
  • Grains, at least half of which are whole grains
  • Fat-free or low-fat dairy
  • A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds
  • This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium.
Experimental: Medium Chain Triglyceride Supplemented DGA
7 days of a diet consistent with the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
Experimental: Ketogenic Diet
7 days of a ketogenic diet (KETO).
A fully provisioned isocaloric, isonitrogenous ketogenic study diet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Asthma Control
Time Frame: Baseline
Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5.
Baseline
Asthma Control
Time Frame: After 7 days on Diet#1
Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5.
After 7 days on Diet#1
Asthma Control
Time Frame: After 7 days on Diet#2
Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5.
After 7 days on Diet#2
Asthma Control
Time Frame: After 7 days on Diet#3
Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5.
After 7 days on Diet#3

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lung Function
Time Frame: Baseline
FEV1 (forced expiratory volume in 1 second; % of predicted)
Baseline
Lung Function
Time Frame: After 7 days on Diet#1
FEV1 (forced expiratory volume in 1 second; % of predicted)
After 7 days on Diet#1
Lung Function
Time Frame: After 7 days on Diet#2
FEV1 (forced expiratory volume in 1 second; % of predicted)
After 7 days on Diet#2
Lung Function
Time Frame: After 7 days on Diet#3
FEV1 (forced expiratory volume in 1 second; % of predicted)
After 7 days on Diet#3
FENO
Time Frame: Baseline
FENO (ppm)
Baseline
FENO
Time Frame: After 7 days on Diet#1
FENO (ppm)
After 7 days on Diet#1
FENO
Time Frame: After 7 days on Diet#2
FENO (ppm)
After 7 days on Diet#2
FENO
Time Frame: After 7 days on Diet#3
FENO (ppm)
After 7 days on Diet#3
FEV1/FVC
Time Frame: Baseline
FEV1/Forced Vital Capacity (FVC) ratio
Baseline
FEV1/FVC
Time Frame: After 7 days on Diet#1
FEV1/Forced Vital Capacity (FVC) ratio
After 7 days on Diet#1
FEV1/FVC
Time Frame: After 7 days on Diet#2
FEV1/Forced Vital Capacity (FVC) ratio
After 7 days on Diet#2
FEV1/FVC
Time Frame: After 7 days on Diet#3
FEV1/Forced Vital Capacity (FVC) ratio
After 7 days on Diet#3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Jacob T Mey, PhD, RD, Pennington Biomedical Research Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 27, 2022

Primary Completion (Actual)

December 18, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

January 5, 2022

First Submitted That Met QC Criteria

January 24, 2022

First Posted (Actual)

February 3, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 3, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • PBRC 2022-001 A

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Study data will be provided upon request and approval by study PI.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on DGA Diet

Subscribe